Tag: KDC-MN-305

  • Vinpocetine

    Synthetic vincamine derivative / cerebrovascular agent

    A synthetic alkaloid derivative of vincamine from Vinca minor; a cerebrovascular agent and PDE1 inhibitor used as a nootropic.

    Abstract

    Vinpocetine ((3-alpha,16-alpha)-eburnamenine-14-carboxylic acid ethyl ester; CAS 42971-09-5; molecular formula C22H26N2O2; molecular weight 350.46) is a synthetic alkaloid derivative of vincamine from Vinca minor (lesser periwinkle), developed at Gedeon Richter (Hungary) in the 1960s and approved in many European countries as Cavinton for cerebrovascular insufficiency. Mechanism is multifactorial: cerebral vasodilation through smooth muscle relaxation, weak phosphodiesterase 1 (PDE1) inhibition, sodium channel block in neurons, and modest antioxidant activity. The combined effect produces improved cerebral blood flow and reduced ischemic neuronal injury in animal stroke models. Plasma half-life is approximately 1 to 2 hours; metabolism is hepatic via CYP2C9 and CYP3A4. Approved indications in Europe include cerebrovascular disorders, age-related cognitive decline, and tinnitus. In the US, the compound is sold as a dietary supplement with FDA reservations about that designation given its drug-like history. Used as a cerebrovascular nootropic and PDE1 inhibitor in research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.